Oculis

CompanySwitzerland

Oculis develops 2 assets, the furthest approved (dexamethasone in burns). Mostly small molecule acting on NR3C1, inflammation and NF-κB signalling; based in Switzerland.

Assets
2
Furthest
Approved
Trials
2
Signals
0

Pipeline

2

  • dexamethasone

    Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects

    ApprovedSmall moleculeNF-κB signallingApoptosisburnsConjunctivitis, Allergic

  • OCS-01

    Ophthalmic formulation of dexamethasone acting as a glucocorticoid receptor agonist to reduce inflammation.

    Phase 3Small moleculeNR3C1Inflammationdiabetic macular edema

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms5
  • Trials2
  • Signals1
  • Similar companies6

Updated 7 Oct 2026 · 61 sources

Intelligence